Skip to content
Screener

Insulet PODD Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$649.1MBeat by $34.9M
EPS$1.17Beat by $0.25
Revenue estimate$614.2M
EPS estimate$0.92

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$833.3M
EPS estimate$1.59

Financials

Q2 2025

Income statement

See full
Revenue$649.1M+32.9%
Gross profit$452.2M+36.7%
Operating income$121.1M+122%
Net income$22.5M-88.1%
EPS (diluted)$0.32-87.6%

Balance sheet

See full
Cash & equivalents$1.1B+36.6%
Total debt$1.9B+26.7%
Total equity$1.5B+46.5%
Total assets$3.5B+20.4%

Cash flow

See full
Operating cash flow$196.5M+126%
CapEx$18.6M-17.3%
Free cash flow$177.9M+177%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$21.88B+55.0%
Enterprise value$22.62B+53.2%
P/E92.7×+57.0×
P/S9.3×+1.7×

Profitability

See full
Gross margin70.7%+1.7pp
Operating margin17.3%+2.7pp
Net margin10%-11.1pp
FCF margin17.2%+7.5pp

Returns & leverage

See full
Return on equity19.2%-31.7pp
Debt / equity1.3×-0.2×
Current ratio2.3×-1.3×

Segments

By product

See full
International$185.8M+44.9%
Drug Delivery$10.2M+25.9%

By geography

See full
U.S.$463.3M—

FAQ

When did Insulet report Q2 2025 earnings?
Insulet (PODD) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Insulet's Q2 2025 revenue and EPS?
Insulet reported revenue of $649.1M and eps of $1.17 for Q2 2025.
Did Insulet beat estimates in Q2 2025?
Revenue beat the consensus estimate of $614.2M by $34.9M. EPS beat the consensus estimate of $0.92 by $0.25.
How did Insulet's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 32.9% from $488.5M a year earlier and eps grew 112.7% from $0.55.
Where can I find Insulet's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001145197-25-000037) and the 10-Q periodic report (0001145197-25-000038) directly on SEC EDGAR. The filing index links above go to sec.gov.